Healios K.K. (OTCMKTS:HLOSF – Get Free Report) was the recipient of a large drop in short interest in March. As of March 13th, there was short interest totaling 502,899 shares, a drop of 33.9% from the February 26th total of 761,032 shares. Based on an average trading volume of 80 shares, the days-to-cover ratio is presently 6,286.2 days.
Healios K.K. Stock Performance
Shares of Healios K.K. stock remained flat at $2.70 during midday trading on Friday. The stock has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $2.84. Healios K.K. has a 52 week low of $1.90 and a 52 week high of $4.45.
About Healios K.K.
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
Featured Stories
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
